These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10410704)

  • 21. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of motor complications in treatment of Parkinson's disease.
    Kumar A; Huang Z; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
    [No Abstract]   [Full Text] [Related]  

  • 23. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers.
    LeWitt PA
    Adv Neurol; 1993; 60():544-7. PubMed ID: 8420188
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
    Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
    Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathophysiology of motor fluctuations in Parkinson's disease.
    Widnell K
    Mov Disord; 2005; 20 Suppl 11():S17-22. PubMed ID: 15822108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.
    Morgante F; Espay AJ; Gunraj C; Lang AE; Chen R
    Brain; 2006 Apr; 129(Pt 4):1059-69. PubMed ID: 16476674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of Parkinson's disease in 2009].
    Maertens de Noordhout A
    Rev Med Suisse; 2009 Aug; 5(214):1650-5. PubMed ID: 19772196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine receptors and locomotor responses: molecular aspects.
    Sealfon SC
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S12-9; discussion S19-21. PubMed ID: 10762128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
    Calabresi P; Giacomini P; Centonze D; Bernardi G
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S60-8; discussion S68-9. PubMed ID: 10762133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The functional anatomy of noradrenergic neurons in Parkinson's disease.
    Soldani P; Fornai F
    Funct Neurol; 1999; 14(2):97-109. PubMed ID: 10399622
    [No Abstract]   [Full Text] [Related]  

  • 37. Serotonin and drug-induced movement disorders.
    Sachdev P
    Aust N Z J Psychiatry; 1994 Dec; 28(4):695-6. PubMed ID: 7794217
    [No Abstract]   [Full Text] [Related]  

  • 38. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated.
    Bezard E; Gross CE; Brotchie JM
    Trends Neurosci; 2003 Apr; 26(4):215-21. PubMed ID: 12689773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
    Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
    Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nondopaminergic mechanisms in levodopa-induced dyskinesia.
    Brotchie JM
    Mov Disord; 2005 Aug; 20(8):919-31. PubMed ID: 16007614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.